These methods include programmable base editing techniques that directly modify the TERTp mutation [57,62], CRISPR-mediated targeting of GA-binding transcription factors that regulate TERT expression [63], and the use of 6-thio-2′-deoxyguanosine [64,65], a telomerase substrate precursor analog, which has shown efficacy in inhibiting tumor cell growth in glioma models. The gene discussed is TERT; the disease is central nervous system cancer.